Literature DB >> 9041949

Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides.

A R Exley1, P A Bacon, R A Luqmani, G D Kitas, C Gordon, C O Savage, D Adu.   

Abstract

OBJECTIVE: To develop and validate the Vasculitis Damage Index (VDI) for the standardized clinical assessment of damage in the systemic vasculitides.
METHODS: Using a nominal group consensus approach, the Birmingham Vasculitis Group generated guiding principles for assessment of damage in all systemic vasculitides. Damage was defined as irreversible change resulting from scars. Consensus principles were developed into the VDI, including guidelines for use, a list of items of damage, and a glossary.
RESULTS: For 100 surviving patients with systemic vasculitis, the median VDI score at last observation was 3 (range 0-8). Within the Wegener's granulomatosis subgroup, the median VDI score for 12 non-survivors was higher than for 47 survivors (non-survivors median score 7, interquartile range 5-8 versus survivors median score 4, interquartile range 2-5; P = 0.003). VDI scores for 100 patients with systemic vasculitis increased from initial presentation to last observation by a median score of 3 (range 1-4; P < 0.001). The VDI assesses more items and is more sensitive to change than other indices of damage (P < 0.001). Using the VDI, trained observers can produce moderately consistent damage scores.
CONCLUSION: The VDI is a sensitive, reproducible, comprehensive, and credible clinical tool for quantifying damage. The data presented herein should enable further validation and testing of the VDI in specific vasculitic syndromes, and should facilitate the comparison of different therapies.

Entities:  

Mesh:

Year:  1997        PMID: 9041949     DOI: 10.1002/art.1780400222

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  131 in total

1.  Monocyte activation in patients with Wegener's granulomatosis.

Authors:  A C Muller Kobold; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

3.  A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature.

Authors:  S F Sørensen; O Slot; N Tvede; J Petersen
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

4.  Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients.

Authors:  Sevil Kamali; Murat Inanc; Ahmet Gul; Lale Ocal; Nuray Gurel Polat; Isin Kilicaslan; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2004-09-15       Impact factor: 2.631

5.  Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Authors:  Ravi Suppiah; Oliver Flossman; Chetan Mukhtyar; Federico Alberici; Bo Baslund; Denise Brown; Nadeem Hasan; Julia Holle; Zdenka Hruskova; David Jayne; Andrew Judge; Mark A Little; Peter A Merkel; Alessandra Palmisano; Philip Seo; Coen Stegeman; Vladimir Tesar; Augusto Vaglio; Kerstin Westman; Raashid Luqmani
Journal:  Ann Rheum Dis       Date:  2010-08-24       Impact factor: 19.103

6.  B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.

Authors:  Lucius Bader; Wenche Koldingsnes; Johannes Nossent
Journal:  Clin Rheumatol       Date:  2010-06-28       Impact factor: 2.980

7.  Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's).

Authors:  Gunnar Tomasson; Maarten Boers; Michael Walsh; Michael LaValley; David Cuthbertson; Simon Carette; John C Davis; Gary S Hoffman; Nader A Khalidi; Carol A Langford; Carol A McAlear; W Joseph McCune; Paul A Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; John H Stone; Steven R Ytterberg; Peter A Merkel
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

8.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Authors:  John H Stone; Peter A Merkel; Robert Spiera; Philip Seo; Carol A Langford; Gary S Hoffman; Cees G M Kallenberg; E William St Clair; Anthony Turkiewicz; Nadia K Tchao; Lisa Webber; Linna Ding; Lourdes P Sejismundo; Kathleen Mieras; David Weitzenkamp; David Ikle; Vicki Seyfert-Margolis; Mark Mueller; Paul Brunetta; Nancy B Allen; Fernando C Fervenza; Duvuru Geetha; Karina A Keogh; Eugene Y Kissin; Paul A Monach; Tobias Peikert; Coen Stegeman; Steven R Ytterberg; Ulrich Specks
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

9.  An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).

Authors:  Carol A Langford; Paul A Monach; Ulrich Specks; Philip Seo; David Cuthbertson; Carol A McAlear; Steven R Ytterberg; Gary S Hoffman; Jeffrey P Krischer; Peter A Merkel
Journal:  Ann Rheum Dis       Date:  2013-12-09       Impact factor: 19.103

10.  Higher levels of SDMA and not ADMA are associated with poorer survival of trial patients with systemic ANCA-associated vasculitis.

Authors:  Uta Erdbrügger; Jan T Kielstein; Kerstin Westman; Jennie Z Ma; Wenjun Xin; Stephanie M Bode-Böger; Mȧrten Segelmark; Niels Rasmussen; Kirsten De Groot
Journal:  Eur J Rheumatol       Date:  2018-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.